Kotra Surveys Horizon

Confirming BMI's predicted trend for Malaysian drugmakers to look abroad for growth, Kotra Pharma has unveiled a 5-year plan that focuses on exports, initially to neighbouring ASEAN countries, but ultimately to the lucrative markets of Western Europe and the US. To achieve this goal, the company intends to expand production capabilities, increase R&D investment, attract world-class talent and enlarge its product portfolio. BMI wholly concurs with Kotra's strategy, especially considering the limited opportunities in its US$1.1bn domestic

To read the full article, please choose one of the following options: